Today

Agents

Chat

Arena

Discover

More

App

Halozyme appoints COUR Pharma CEO Dannielle Appelhans to board - HALO News | Rallies

Halozyme appoints COUR Pharma CEO Dannielle Appelhans to board

HALO•2026-08-18

Appelhans joins Halozyme board

Halozyme elected Dannielle Appelhans to its board of directors.
Appelhans has been CEO of COUR Pharmaceuticals since 2023, leading a Genentech collaboration valued up to $1 billion.
She previously served as CEO of Rubius Therapeutics.
Earlier roles included senior operations and supply chain leadership at Novartis Gene Therapies, supporting Zolgensma manufacturing and delivery.

Related News

Value Line announces annual shareholder meeting

VALU•2026-08-18

Cosmos Health Q2 FY26 net loss widens 115.2% to $6.09 million; revenue rises 28.8% to $18.99 million

COSM•2026-08-18

Rocket Lab wins USD 12 million in U.S. Space Force Space Data Network delivery orders

•

2026-08-18

Exozymes says optimized NCT process lifts manufacturing productivity 10-fold

EXOZ•2026-08-18

Boost Run Q2 FY26 net loss widens to $75.05 million; revenue rises to $31.14 million

BRUN•2026-08-18